Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II stud (Q39612713)
Jump to navigation
Jump to search
scientific article published on June 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II stud |
scientific article published on June 2012 |
Statements
1 reference
Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II stud (English)
1 reference
Pedro Sánchez-Rovira
1 reference
Antonio Antón
1 reference
Agustí Barnadas
1 reference
Amalia Velasco
1 reference
María Lomas
1 reference
María Rodríguez-Pinilla
1 reference
José Luis Ramírez
1 reference
César Ramírez
1 reference
María José Ríos
1 reference
Eva Castellá
1 reference
Carmen García-Andrade
1 reference
Belén San Antonio
1 reference
Eva Carrasco
1 reference
José Luis Palacios
1 reference
1 June 2012
1 reference
1 reference
14
1 reference
6
1 reference
430-436
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference